Item Development Ab

Item Development Aktiebolag

Item Development Inc.

Solimedco Aktiebolag

Alf Sollevi

This invention is concerned with the use of adenosine as an agent for the treatment of human beings. More particularly, this invention is concerned with the administration of adenosine to human patients by continuous intravenous infusion for, inter alia, control of blood pressure, use as a selective vasodilator, decreasing pulmonary vascular resistance, treating acute pulmonary hypertension in conjunction with idiopathic respiratory distress syndrome, in diagnosing pulmonary hypertension in conjunction with cardiac septum defects, in percutaneous transluminal angioplasty (PTCA), in coronary thrombolysis (CTL) and in radionucleide scintography.

Selective vasodilation by continuous adenosine infusion

Method of treating hyperexcited sensory nerve function

The described invention relates to a method of treatment of a pulmonary inflammatory reaction brought about by e.g. bacteraemia, physical trauma or viral infection, with activation of polymorphonuclear white blood cells, said method comprising continuous intravenous infusion of adenosine at a rate effective for such treatment, preferably 2 to 50 .mu.g/ml/min, more preferably 5-20 .mu.g/kg/min in a central vein.

Method of treating pulmonary inflammation by continuous administration

Treating myocardial infarction by administration of a thrombolytic agent

Continuous intravenous infusion of adenosine to human patients

Continuous administration adenosine to increase myocardial blood flow

This invention is concerned with the use of adenosine as an agent for the treatment of human beings. More particularly, this invention is concerned with the administration of adenosine to human patients by continuous intravenous infusion for, inter alia, control of blood pressure, use as a selective vasodilator, decreasing pulmonary vascular resistance, treating acute pulmonary hypertension in conjunction with idiopathic respiratory distress syndrome, in diagnosing pulmonary hypertension in conjunction with cardiac septum defects, in percutaneous transluminal angioplasty (PTCA), in coronary thrombolysis (CTL), and in radionucleide scintography.

Continuous administration of adenosine to reduce pulmonary vascular

Growing community of inventors

Bromma, Sweden

Alf Sollevi